Cover Image
Read Now

Biosimilars in Europe

This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries.

Bibliographic Details
Main Author: Vulto, Arnold G.
Other Authors: Simoens, Steven, Huys, Isabelle
Format: eBook
Language:English
Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
Subjects:
Germany
Reimbursement
Biosimilar/supply And Distribution
Drug Costs
N/a
Savings
Biosimilars
Incentives
Biosimilarity Assessment
Pharmaceutical Spending
Pricing
Clinical Governance
Review
Cost Simulation
Procurement
Communication
Quality Attributes (qas)
Europe
Approval
Biological
Potentially Critical Quality Attributes (pcqas)
Etanercept
Subcutaneous
Tnfα Inhibitors
Her2-positive Breast Cancer
Clinical
Biosimilar Sustainability
Biologics
Education
Patient
Market Dynamics
Manufacturing Industries / Bicssc
Healthcare Costs
Reference Biological
Belgium
Budget Impact Analysis
Infliximab
Award Criteria
Biosimilar
Barriers
Cost Containment
Regulatory
Intravenous
European Public Assessment Reports (epars)
Biosimilar Market
Regulatory Science
Off-patent
Sustainability
Delphi Technique
Switching
Competition
Queries
Competitive Market
Adalimumab
Trastuzumab
Medicine And Nursing / Bicssc
Spain
Interchangeability
Utilization
Tender
Information
Uptake
Policies
Online Access:
Collection: Directory of Open Access Books - Collection details see MPG.ReNa
Description
Summary:This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries.
Item Description:Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
Physical Description:1 electronic resource (188 p.)
ISBN:9783036565743
9783036565750
books978-3-0365-6574-3

Similar Items